Use of ultrarapid acting insulin
US9943571B2 · kind B2 · utility
0Cited by
882References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 10, 2013 |
| Grant date | Apr 17, 2018 |
| Priority date | — |
| Expiry date | Jul 23, 2034 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.